No Way To Go But Grow: J&J Outlines Plans To Become A $60bn Pharma In 2025
Executive Summary
Management outlined its growth strategy to investors, highlighting plans to file 14 novel drugs with more than $1bn in peak sales by 2025.
You may also be interested in...
Ipsen To Exit Consumer Health And Focus On Specialty Pharma
The French group is sharpening its focus on specialty care in oncology, rare disease and neuroscience, so is looking to divest its consumer health division to Mayoly Spindler.
J&J, Flush With Cash, Has Flexibility To Be ‘Bolder’ On M&A, CEO Duato Says
The company kicked off the new year with a new CEO, plans to break out consumer health, and a strong financial position, including $32bn in cash and lowest level of net debt in more than four years.
Q4 Earnings Preview: Setting The Tone For 2022 (Part 1)
Biopharma will outline its growth goals for 2022 over the coming weeks, with J&J, Novartis, AbbVie, Merck, Roche, Biogen and Lilly among the first to report.